Decapeptyl SR
Print

DECAPEPTYL® SR 3MG, 11.25MG & 22.5MG - TRIPTORELIN

Decapeptyl<sup>®</sup> SR 3mg, 11.25mg & 22.5mg - triptorelin

Description

Decapeptyl® SR 3mg Triptorelin (I.N.N.) 4.2 mg, as triptorelin acetate. Powder for suspension for injection, sustained release formulation.

Decapeptyl® SR 11.25mg Triptorelin (I.N.N.) 15 mg, as triptorelin acetate. Powder for suspension for injection, sustained release formulation.

Decapeptyl® SR 22.5mg Triptorelin (I.N.N.) 28 mg, as triptorelin pamoate. Powder for suspension for injection, sustained release formulation.

Active substance

Triptorelin

Decapeptyl® SR 3mg is indicated for:

  • Treatment of locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
  • Treatment of metastatic prostate cancer.
  • As adjuvant, or neoadjuvant treatment prior to radiotherapy, in patients with high-risk localised or locally advanced prostate cancer.
  • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high-risk of disease progression.
  • Treatment of endometriosis.
  • Treatment of uterine fibroids prior to surgery or when surgery is not appropriate.

Decapeptyl® SR 11.25mg is indicated for:

  • Treatment of locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
  • Treatment of metastatic prostate cancer.
  • As adjuvant, or neoadjuvant treatment prior to radiotherapy, in patients with high-risk localised or locally advanced prostate cancer.
  • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high-risk of disease progression.
  • Treatment of endometriosis.
  • Treatment of precocious puberty (onset before 8 years in girls and 10 years in boys).

Decapeptyl® SR 22.5mg is indicated for:

  • Treatment of locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
  • Treatment of metastatic prostate cancer.
  • As adjuvant, or neoadjuvant treatment prior to radiotherapy, in patients with high-risk localised or locally advanced prostate cancer.
  • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high-risk of disease progression.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to the Ipsen Medical Information Department on 01753 627777 or medical.information.uk@ipsen.com